Lakefront Biotherapeutics | GLPG - Ebitda


Lakefront Biotherapeutics reported EUR-63.7M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
argenx SE USD 539M 6M Sep/2026
AstraZeneca USD 5.16B 510M Jun/2026
Biogen USD 649.7M 76.5M Mar/2026
Genmab DKK 401M 186M Jun/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
GRIFOLS EUR 473M 120M Jun/2026
Hikma Pharmaceutical USD 369M 84M Dec/2024
Incyte USD 778.57M 410.6M Jun/2026
Merck EUR 1.6B 69M Jun/2026
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sanofi EUR 3.69B 375M Jun/2026
UCB EUR 1.6B 570M Dec/2025
Vertex Pharmaceuticals USD 1.33B 130.5M Jun/2026